Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones
Rhea-AI Summary
Annexon (NASDAQ: ANNX) reported its Q4 and full-year 2024 financial results, highlighting progress across its late-stage clinical platform. The company maintains a strong financial position with $312 million in cash and investments as of December 31, 2024, providing runway into H2 2026.
Key developments include:
- ANX005 for Guillain-Barré Syndrome (GBS) advancing toward pre-BLA meeting in H1 2025
- Established global registration path for ANX007 as potential first vision-preserving treatment for dry AMD with GA
- Ongoing proof-of-concept trial for ANX1502, first-in-kind oral C1s inhibitor
Financial results show R&D expenses of $43.4M for Q4 2024 ($119.4M full-year), compared to $23.3M in Q4 2023 ($113.8M full-year). Net loss was $48.6M for Q4 2024 ($138.2M full-year), versus $27.9M in Q4 2023 ($134.2M full-year).
Positive
- Strong cash position of $312M providing runway into H2 2026
- Established global registration pathway for ANX007 in both Europe and US
- ANX005 showed positive Phase 3 results for GBS treatment
- ANX007 demonstrated significant vision preservation in Phase 2 ARCHER trial
Negative
- Increased net loss to $138.2M in 2024 from $134.2M in 2023
- R&D expenses increased to $43.4M in Q4 2024 from $23.3M in Q4 2023
- Phase 3 ARCHER II trial results not expected until H2 2026
Insights
Annexon's Q4 and FY2024 results reflect substantial investment acceleration in their late-stage pipeline, with R&D expenses surging 86% YoY to
The company's strong balance sheet position of
Operating losses increased to
The regulatory progress for ANX007 is particularly noteworthy, having secured a streamlined global registration path that could substantially reduce time-to-market and development costs. This demonstrates savvy regulatory strategy execution in a competitive ophthalmology market where first-mover advantage can be critical.
Annexon's classical complement inhibition platform is delivering promising results across multiple indications, with each program targeting complement-mediated neuroinflammation through different delivery mechanisms – a strategic approach that maximizes the platform's potential.
ANX005's GBS data package appears comprehensive and methodically constructed over nine years, including placebo-controlled trials and supporting real-world evidence studies. The reported functional recovery improvements versus placebo provide a compelling efficacy narrative. The drug-drug interaction study with IVIg further strengthens its clinical profile, addressing a critical safety consideration for actual treatment settings.
The regulatory strategy for ANX007 represents a significant achievement – securing a single pivotal Phase 3 trial that will be analyzed as two sub-studies for FDA purposes is an elegant solution to satisfy the agency's two-trial recommendation while maintaining trial efficiency. The selection of vision preservation (preventing ≥15-letter BCVA loss) as the primary endpoint is patient-centric and clinically meaningful.
ANX1502 represents the company's most innovative approach – an oral small molecule targeting C1s rather than using antibodies. The ability to achieve 4-5× target concentration with flexible oral dosing could allow precise inhibition titration. Early signs of hemolysis reduction in CAD patients suggest target engagement, though the small patient number (three) necessitates caution in interpretation pending the expanded dataset.
Robust, Consistent Phase 3 Data and Real-World Evidence Outcomes Support ANX005 as Potential First Targeted Therapy for GBS; Pre-BLA Meeting Targeted for 1H 2025 Ahead of Planned Biologics License Application (BLA) Submission
Established Groundbreaking Global Registration Path for ANX007 to be Potential First Vision-Preserving Treatment for Dry AMD with GA in Europe and U.S.; Topline Phase 3 ARCHER II Data Expected Second Half 2026
First-in-Kind Oral C1s Inhibitor POC Trial Ongoing with Dosing in Three Patients with Cold Agglutin Disease; Expanded ANX1502 Dataset to Include Up to Seven Patients Expected Mid-2025
Strong Balance Sheet with Cash, Cash Equivalents, and Short-term Investments of Approximately
BRISBANE, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today highlighted portfolio progress and reported fourth quarter and full year 2024 financial results.
“Our 10-year journey has focused on disrupting the classical complement space by delivering multiple transformative treatments for neuroinflammatory diseases of the body, brain and eye. Importantly, our three flagship programs are showing tremendous promise to be game-changing, best-in-class therapies in their respective blockbuster therapeutic markets,” said Douglas Love, president and chief executive officer of Annexon. “Our lead program, ANX005 for the treatment of Guillain-Barré Syndrome (GBS), has consistently demonstrated early and durable functional improvements with a differentiated safety profile, offering the potential to help the tens of thousands of patients annually whose lives are suddenly turned upside down by this devastating disease. We look forward to the pre-BLA meeting with FDA targeted for the first half of 2025 ahead of our BLA submission.”
Mr. Love continued, “We are also enthusiastic about recent positive regulatory engagements resulting in a groundbreaking global registration path for ANX007 to become the potential first drug approved in Europe and the U.S. for dry age-related macular degeneration (AMD) with geographic atrophy (GA) based on the global Phase 3 ARCHER II program. As demonstrated in the Phase 2 ARCHER trial, ANX007 is the only program to have shown significant vision preservation as well as significant preservation of central retina photoreceptor neurons responsible for visual acuity. Finally, in patients treated with the oral small molecule ANX1502, we are encouraged by the changes in multiple measures of hemolysis consistent with complement inhibition. Our ongoing ANX1502 proof-of-concept (POC) trial is designed to build a robust dataset in up to seven patients with data expected mid-2025. Strong execution continues across our portfolio, and we are well-positioned for a breakthrough year.”
Recent Corporate and Clinical Program Updates
Flagship Programs
ANX005 in Guillain-Barré Syndrome (GBS): First-in-kind monoclonal antibody designed to block C1q, the initiating molecule of the classical complement cascade, with a single infusion to halt ongoing neuroinflammation and nerve damage in the acute phase of disease with potential to be the first targeted therapy for GBS.
- A robust data package has been generated with close regulatory guidance over the nine year development path that includes a placebo-controlled Phase 1b trial that established POC for ANX005 as a first-line treatment for GBS, a successful Phase 3 trial showing that ANX005 was generally well tolerated and resulted in faster and more complete functional recovery versus placebo, a Real-World Evidence (RWE) study that showed improved outcomes against current standards of care in matched patient populations, and a drug-drug interaction study with ANX005 and intravenous immunoglobulin (IVIg) strengthening the safety profile for ANX005 in GBS
- Phase 3 data to be featured in an oral presentation on Tuesday, April 8 at the upcoming American Academy of Neurology (AAN) 2025 Annual Meeting taking place April 5–9, 2025, in San Diego, California. Abstracts for AAN will be released on Thursday, March 6
- GBS is a rare, neuromuscular emergency that affects at least 150,000 people worldwide each year, with no FDA-approved therapy. The life-altering consequences of GBS were recently detailed in a new patient survey released by the GBS/CIDP Foundation that underscores the significant unmet need notwithstanding standard of care
- Next Milestone: Pre-BLA meeting targeted for first half of 2025 ahead of planned BLA submission
ANX007 in Dry Age-Related Macular Degeneration (AMD) Patients with Geographic Atrophy (GA): First-in-kind, non-pegylated antigen-binding fragment (Fab) designed to block C1q and the classical complement cascade locally in the eye.
- Following positive engagement with EU and U.S. regulators regarding the Phase 3 ARCHER II trial design, groundbreaking global registration path established supporting the potential of ANX007 to be the first treatment approved in both Europe and the U.S. for protection of vision in patients who have dry AMD with GA. ANX007 is also the only program to receive PRIME designation from the European Medicines Agency for GA
- ANX007 is the first and only investigational therapy to show significant vision preservation on assessments of best corrected visual acuity (BCVA) and low luminance visual acuity, demonstrating significant protection from vision loss in both normal and low light conditions, as well as significant preservation of central retinal photoreceptors necessary for visual acuity as demonstrated in the Phase 2 ARCHER trial
- ARCHER II is a global, sham-controlled, double-masked, Phase 3 trial enrolling approximately 630 patients who have dry AMD with GA. The single-study program will be analyzed as two sub-studies for the U.S. in accordance with the FDA’s two-trial recommendation. The primary endpoint of ARCHER II is prevention of ≥15-letter loss of BCVA, and an objective secondary structural measure is prevention of ellipsoid zone loss, both of which measures were met in the Phase 2 ARCHER trial. Accordingly, Annexon no longer plans to conduct a second injection-controlled head-to-head Phase 3 trial
- Dry AMD with GA is a leading cause of blindness affecting more than 8 million patients worldwide, and there are no approved therapies targeting the preservation of vision in this disease
- Next Milestone: Phase 3 ARCHER II trial enrollment expected to be completed in second half of 2025; data expected in second half of 2026
ANX1502 for Autoimmune Conditions: First-in-kind oral small molecule inhibiting the activated form of C1s, an enzyme associated with C1q to drive initiation of the classical cascade, has the potential to offer the advantages of selective upstream classical complement inhibition with the convenience and flexibility of oral administration.
- An ongoing open-label, single arm, POC study is evaluating ANX1502 in patients with cold agglutinin disease (CAD) for up to four weeks to evaluate tolerability, pharmacokinetics, pharmacodynamic and clinical efficacy endpoints (e.g., hemolysis as measured by reduction of elevated bilirubin)
- Enteric coated tablets allow flexible dosing 4-5-times above target concentrations of 100nM for rigorous testing in CAD, a classical complement-mediated disease
- Three patients enrolled to date with observed reduction in key clinical and biomarker outcomes consistent with complement inhibition; awaiting full data
- Next Milestone: Dataset in up to seven CAD patients to be reported in mid-2025
Expanded board of directors with addition of William “BJ” Jones, M.B.A: Mr. Jones brings 30 years of U.S. and global commercial and launch experience in the biotechnology industry. Mr. Jones joins Annexon with demonstrated commercial success at both large pharmaceutical and small biotechnology companies, with experience driving mass-market product launch strategies for industry-leading brands. He currently serves as the chief commercial officer of NewAmsterdam Pharma Company N.V. where he leads all commercial functions, including marketing, market access, sales, medical science engagement and commercial operations.
Fourth Quarter and Full Year 2024 Financial Results
- Cash and operating runway: Cash, cash equivalents and short-term investments were
$312.0 million as of December 31, 2024. Annexon continues to expect its cash, cash equivalents and short-term investments as of December 31, 2024, to be sufficient to fund its planned operating expenses into the second half of 2026 - Research and development (R&D) expenses: R&D expenses were
$43.4 million for the quarter ended December 31, 2024, and$119.4 million for the year ended December 31, 2024, reflecting the advancement of Annexon’s priority programs, including GBS, dry AMD with GA and ANX1502, compared to$23.3 million for the quarter ended December 31, 2023, and$113.8 million for the year ended December 31, 2023 - General and administrative (G&A) expenses: G&A expenses were
$9.1 million for the quarter ended December 31, 2024, and$34.6 million for the year ended December 31, 2024, compared to$6.7 million for the quarter ended December 31, 2023, and$30.0 million for the year ended December 31, 2023 - Net loss: Net loss was
$48.6 million for the quarter ended December 31, 2024, and$138.2 million for the year ended December 31, 2024, compared to$27.9 million for the quarter ended December 31, 2023, and$134.2 million for the year ended December 31, 2023
About Annexon
Annexon Biosciences (Nasdaq: ANNX) is developing therapeutics that stop classical complement-driven neurodegeneration as first-in-kind treatments for millions of people living with serious neuroinflammatory diseases of the body, brain and eye. Our novel scientific approach focuses on C1q, the initiating molecule of classical complement’s potent inflammatory pathway that when misdirected can lead to tissue damage and loss. By targeting C1q, our immunotherapies are designed to stop this neuroinflammatory cascade in disease before it starts. Our pipeline spans three diverse therapeutic areas – autoimmune, neurodegenerative and ophthalmic diseases – and includes targeted investigational drug candidates designed to address the unmet needs of over 8 million people worldwide. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements about: the potential therapeutic benefit of ANX005, if approved, compared to existing therapies; anticipated timing of the pre-BLA meeting and BLA submission for ANX005; potential benefit of ANX005, if approved, compared to intravenous immunoglobulin /plasma exchange or other existing therapies; the company’s ability to achieve regulatory approval for ANX005; the potential therapeutic benefit of ANX007; timing of completion of enrollment and results from the Phase 3 ARCHER II trial; ANX007’s distinct potential neuroprotective mechanism of action and potential to provide protection from vision loss; the potential for ANX007 to be the first drug approved in Europe and the U.S. for dry AMD with GA; timing of proof-of-concept data for ANX1502; the company’s ability to commercialize its product candidates, if approved; continued development of ANX007 and ANX1502; anticipated cash runway into the second half of 2026; the potential benefits from treatment with anti-C1q therapy; and continuing advancement of the company’s portfolio. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: the final results from the Phase 3 ARCHER II trial; the company’s history of net operating losses; the company’s ability to obtain necessary capital to fund its clinical programs; the early stages of clinical development of the company’s product candidates; the effects of public health crises on the company’s clinical programs and business operations; the company’s ability to obtain regulatory approval of and successfully commercialize its product candidates; any undesirable side effects or other properties of the company’s product candidates; the company’s reliance on third-party suppliers and manufacturers; the outcomes of any future collaboration agreements; and the company’s ability to adequately maintain intellectual property rights for its product candidates. These and other risks are described in greater detail under the section titled “Risk Factors” contained in the company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and the company’s other filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, the company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
Media Contact:
Sheryl Seapy
Real Chemistry
949-903-4750
sseapy@realchemistry.com
| ANNEXON, INC. Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) | ||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development (1) | $ | 43,354 | $ | 23,267 | $ | 119,448 | $ | 113,756 | ||||||||
| General and administrative (1) | 9,125 | 6,742 | 34,625 | 29,967 | ||||||||||||
| Total operating expenses | 52,479 | 30,009 | 154,073 | 143,723 | ||||||||||||
| Loss from operations | (52,479 | ) | (30,009 | ) | (154,073 | ) | (143,723 | ) | ||||||||
| Interest and other income, net | 3,889 | 2,118 | 15,873 | 9,486 | ||||||||||||
| Net loss | $ | (48,590 | ) | $ | (27,891 | ) | $ | (138,200 | ) | $ | (134,237 | ) | ||||
| Net loss per share, basic and diluted | $ | (0.33 | ) | $ | (0.36 | ) | $ | (1.01 | ) | $ | (1.77 | ) | ||||
| Weighted-average shares used in computing net loss per share, basic and diluted | 147,812,160 | 78,217,945 | 137,404,145 | 75,673,081 | ||||||||||||
_______________________
| (1) Includes the following stock-based compensation expense: | ||||||||||||||||
| Research and development | $ | 2,752 | $ | 2,077 | $ | 9,670 | $ | 8,878 | ||||||||
| General and administrative | $ | 2,470 | $ | 2,290 | $ | 9,763 | $ | 9,305 | ||||||||
| ANNEXON, INC. Condensed Consolidated Balance Sheets (in thousands) | ||||||||
| December 31 | ||||||||
| 2024 | 2023 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 49,498 | $ | 225,110 | ||||
| Short-term investments | 262,519 | 34,606 | ||||||
| Prepaid expenses and other current assets | 4,444 | 4,144 | ||||||
| Total current assets | 316,461 | 263,860 | ||||||
| Restricted cash | 1,032 | 1,032 | ||||||
| Property and equipment, net | 12,638 | 14,773 | ||||||
| Operating lease right-of-use assets | 16,705 | 18,009 | ||||||
| Other non-current assets | 3,235 | — | ||||||
| Total assets | $ | 350,071 | $ | 297,674 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 10,426 | $ | 5,487 | ||||
| Accrued and other current liabilities | 17,568 | 10,276 | ||||||
| Operating lease liabilities, current | 2,518 | 2,165 | ||||||
| Total current liabilities | 30,512 | 17,928 | ||||||
| Operating lease liabilities, non-current | 26,454 | 29,190 | ||||||
| Total liabilities | 56,966 | 47,118 | ||||||
| Stockholders’ equity: | ||||||||
| Common stock | 109 | 78 | ||||||
| Additional paid-in capital | 1,003,685 | 823,029 | ||||||
| Accumulated other comprehensive loss | 10 | (52 | ) | |||||
| Accumulated deficit | (710,699 | ) | (572,499 | ) | ||||
| Total stockholders' equity | 293,105 | 250,556 | ||||||
| Total liabilities and stockholders’ equity | $ | 350,071 | $ | 297,674 | ||||
FAQ
What are the key milestones expected for Annexon's ANX005 GBS treatment in 2025?
When will Annexon report Phase 3 ARCHER II trial results for ANX007?
What is the current cash position of ANNX and expected runway?
What were Annexon's R&D expenses for full-year 2024?
When will ANNX report expanded data for ANX1502 in CAD patients?
